organization · Reporting owner
Avalo Therapeutics, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | 10% owner | April 15, 2020 | April 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date April 15, 2020 · Filed April 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,713,068 |
Ending reported balance
After 2020-04-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-04-10 · Conversion · Acquired 9,805,845 · Balance 9,805,845 F1: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date. Row 2 · 2020-04-15 · Sale · Disposed 92,777 · Balance 9,713,068 |
| Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-04-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-10 · Conversion · Disposed 9,805,845 · Balance 0 F1: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2020 Filed Apr 27, 2020 13:30 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | SaleCommon Stock | 92,777 | $1.55 | $144,091.96 |
DisclosureSEC source: 0001578563-20-000020 · primary_doc.xml · nonDerivative · entry 2 Cerecor Inc. · CIK 0001534120 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,713,068 Read SEC document |
| April 10, 2020 Filed Apr 27, 2020 13:30 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | ConversionConvertible Preferred Stock · Derivative | 9,805,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-20-000020 · primary_doc.xml · derivative · entry 3 Cerecor Inc. · CIK 0001534120 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,805,845 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date. F1 · derivative.exercise_date: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date. F1 · derivative.expiration_date: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date. Read SEC document |
| April 10, 2020 Filed Apr 27, 2020 13:30 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | ConversionCommon Stock | 9,805,845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-20-000020 · primary_doc.xml · nonDerivative · entry 1 Cerecor Inc. · CIK 0001534120 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,805,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of the Issuer's convertible preferred stock were convertible into shares of the Issuer's common stock upon the expiration of the Reporting Person's Lock-Up Agreement with the Issuer, which was accelerated, on a one-for-one basis at the option of the Reporting Person upon distribution to the Reporting Person's stockholders or upon a sale. The convertible preferred stock has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.